CytomX Therapeutics (CTMX) IPO Opens Sharply Higher, Pares Gains
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
CytomX Therapeutics (CTMX) IPO Prices at $12, Below Expected Range
October 8, 2015 8:51 AM EDTCytomX Therapeutics, Inc. (NASDAQ: CTMX) announced the pricing of its initial public offering of 6,666,667 shares of common stock at an initial public offering price of $12 per share, below the $14-$16 range. The shares are expected to begin trading on the NASDAQ Global Select Market today under the ticker symbol "CTMX."
In addition, the underwriters have a 30-day option to purchase up to an additional 1,000,000 shares of common stock from CytomX. All shares of common stock are being offered by CytomX.... More
